LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Search

Heron Therapeutics Inc

Închisă

SectorSănătate

1.32 1.54

Rezumat

Modificarea prețului

24h

Curent

Minim

1.31

Maxim

1.33

Indicatori cheie

By Trading Economics

Venit

-15M

-17M

Vânzări

1M

38M

EPS

-0.036

Marjă de profit

-45.783

Angajați

122

EBITDA

-12M

-14M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+243.51% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-5.4M

211M

Deschiderea anterioară

-0.22

Închiderea anterioară

1.32

Sentimentul știrilor

By Acuity

32%

68%

80 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Heron Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 dec. 2025, 21:08 UTC

Achiziții, Fuziuni, Preluări

Meta Platforms Buys AI-Device Maker Limitless

5 dec. 2025, 19:39 UTC

Principalele dinamici ale pieței

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 dec. 2025, 19:17 UTC

Achiziții, Fuziuni, Preluări

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

6 dec. 2025, 16:52 UTC

Achiziții, Fuziuni, Preluări

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6 dec. 2025, 10:30 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6 dec. 2025, 02:38 UTC

Achiziții, Fuziuni, Preluări

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5 dec. 2025, 21:59 UTC

Achiziții, Fuziuni, Preluări

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 dec. 2025, 21:50 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

5 dec. 2025, 21:50 UTC

Achiziții, Fuziuni, Preluări

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 dec. 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 dec. 2025, 21:35 UTC

Achiziții, Fuziuni, Preluări

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 dec. 2025, 21:26 UTC

Achiziții, Fuziuni, Preluări

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 dec. 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 dec. 2025, 21:03 UTC

Market Talk
Câștiguri

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 dec. 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 dec. 2025, 20:43 UTC

Achiziții, Fuziuni, Preluări

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 dec. 2025, 20:43 UTC

Achiziții, Fuziuni, Preluări

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 dec. 2025, 20:42 UTC

Achiziții, Fuziuni, Preluări

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 dec. 2025, 20:01 UTC

Achiziții, Fuziuni, Preluări

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 dec. 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 dec. 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 dec. 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5 dec. 2025, 19:31 UTC

Achiziții, Fuziuni, Preluări

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec. 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 dec. 2025, 18:28 UTC

Achiziții, Fuziuni, Preluări

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec. 2025, 18:24 UTC

Achiziții, Fuziuni, Preluări

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5 dec. 2025, 18:20 UTC

Market Talk

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5 dec. 2025, 18:11 UTC

Market Talk

The Tale of Two Canadian Employment Indicators -- Market Talk

5 dec. 2025, 17:48 UTC

Market Talk

Canadian Youth Unemployment Rate Cools -- Market Talk

5 dec. 2025, 17:44 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Equities Roundup: Market Talk

Comparație

Modificare preț

Heron Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

243.51% sus

Prognoză pe 12 luni

Medie 4.5 USD  243.51%

Maxim 6 USD

Minim 3 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHeron Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

4

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.0001 / 2.42Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

80 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat